NUSADAILY.COM – JAKARTA – Internal Medicine Specialist from the Faculty of Medicine, Tarumanagara University (FK Untar) dr Velma Herwanto SpPD PhD said the COVID-19 vaccine can help reduce the spread of the virus in the community.
“The vaccine works by protecting individuals against SARS-CoV-2 virus infection. If the infection persists, the degree of weight of the disease will be milder. The more people vaccinated, the more immunity will be formed,” Velma said in her written statement in Jakarta, Sunday.
He added that the vaccine used in Indonesia is classified as safe because it has been through clinical trials. From these clinical trials it was concluded that the vaccine proved safe. Side effects that arise minimally, such as fever, chills, headaches and fatigue. “No severe side effects were reported, except for anaphylactic allergic reactions that commonly arise in people who have a previous history of drug allergies. That risk is minimized by conducting surveillance for 30 minutes after vaccination.
Velma also suggested that the government actively socialize about vaccinations, especially related to its safety through many things.
“In addition to calling for vaccination, the government should also submit data on the efficacy and safety of vaccines, both through interactive visuals, the delivery of data in the form of numbers, as well as personal approaches with the help of community leaders and officials to convince the public that vaccines are safe to use,” he said.
Meanwhile, health start-up SehatQ said the results of the survey showed that most people are willing to accept the COVID-19 vaccine.
“We have conducted a survey to explore public perception of the COVID-19 vaccine. The survey, conducted online in October 2020, involved 797 respondents. The results of the survey successfully mapped the public’s view on the presence of vaccines during the current pandemic,” said SehatQ CEO Linda Wijaya.
In terms of vaccine delivery time, the majority of respondents, namely as many as 49 percent, expect mass vaccination to be carried out if the quality of the vaccine has been proven effective. Meanwhile, 19 percent of respondents (155 people) wanted vaccinations done immediately. Furthermore, 10 percent (76 people) and 9 percent (74 people) chose to get the vaccine as scheduled by the government and after the priority group received it.
SehatQ also dug up information from respondents who were not yet willing to accept the vaccine. At least 12 percent of respondents (98 out of 797 people) rejected the vaccine for four reasons. First, the respondents (66 percent of respondents or 98 people who refused) were unsure of the safety or effectiveness of the COVID-19 vaccine. Second, as many as 19 percent (19 people) of respondents worried about side effects in the future. Third, 8 percent of respondents (8 people) believe there are alternatives to vaccines to end the pandemic. Fourth, religious belief considerations led 6 percent of respondents (6 people) to reject the COVID-19 vaccine.
Senior Executive Vice President (SEVP) of Bio Farma Research and Development, Drs. Adriansjah Azhari Apt MM, said the public should not worry about the quality and safety of the COVID-19 vaccine circulating in the country.
“Before it was distributed to the public, the research team, together with the medical team, conducted rigorous testing of the vaccine,” Adriansjah said. (eky)